Boehringer Ingelheim
Sarah O'Brien is a highly experienced immuno-oncology research scientist currently serving as a Senior Principal Scientist in Cancer Immunology and Immune Modulation at Boehringer Ingelheim, a position held since June 2021. Prior experience includes roles at Amgen as Principal Scientist and Scientist, where significant contributions were made to early-stage Discovery Projects aimed at enhancing anti-tumor T cell responses. Additional expertise includes freelance writing for the American Association for Cancer Research and conducting research as a Graduate Research Assistant at Duke University, where a Ph.D. in Immunology was obtained. O'Brien also holds a B.S. in Biology from the University of Notre Dame and has served as a consultant and undergraduate research assistant in various academic settings.
This person is not in any teams
This person is not in any offices
Boehringer Ingelheim
116 followers
At Boehringer Ingelheim they create value through innovation with one clear goal: to improve the lives of patients. They develop breakthrough therapies and innovative healthcare solutions in areas of unmet medical need for both humans and animals. As a family owned company, they focus on long-term performance. They are powered by 50.000 employees globally who nurture a diverse, collaborative and inclusive culture. Learning and development for all employees is key, because your growth is their growth.